

Susan Halabi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9161296/susan-halabi-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

305
papers

18,480
citations

61
h-index

133
g-index

351
ext. papers

21,422
ext. citations

4.6
avg, IF

6.05
L-index

#	Paper	IF	Citations
305	Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 106-106	2.2	1
304	Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 107-107	2.2	2
303	Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 139-139	2.2	
302	HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 370-370	2.2	
301	Factorial Trials 2021 , 1-25		
300	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2134330	10.4	8
299	Variable Selection Approaches in High-Dimensional Space. <i>Emerging Topics in Statistics and Biostatistics</i> , 2021 , 301-327	0.2	0
298	Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2021 , 19, 64-72	0.1	1
297	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , 2021 , 22, 402-410	21.7	21
296	Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , 2021 , 19, 1040-1050	6.6	4
295	On the design and the analysis of stratified biomarker trials in the presence of measurement error. <i>Statistics in Medicine</i> , 2021 , 40, 2783-2799	2.3	
294	A semiparametric modeling approach for analyzing clinical biomarkers restricted to limits of detection. <i>Pharmaceutical Statistics</i> , 2021 , 20, 1061-1073	1	
293	In-depth analysis of the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) - The importance of representation of medical specialty and geographic regions. <i>European Urology Open Science</i> , 2021 , 26, 14-17	0.9	1
292	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021 , 27, 4077-4088	12.9	5
291	Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5057-5057	2.2	1
290	A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. <i>Cancer</i> , 2021 , 127, 2954-2965	6.4	7
289	Estimand framework: Are we asking the right questions? A case study in the solid tumor setting. <i>Pharmaceutical Statistics</i> , 2021 , 20, 324-334	1	3

288	Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 1271-1278	4	2
287	Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 154-154	2.2	
286	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3317-3328	12.9	4
285	Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 157-157	2.2	
284	Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 39-39	2.2	5
283	Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 89-89	2.2	2
282	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. <i>European Urology Oncology</i> , 2021 ,	6.7	3
281	Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2443-2451	2.2	27
280	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021 , 144, 1295-1307	16.7	13
279	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021 , 39, 2486-2496	2.2	10
278	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021 , 30, 47-62	0.9	2
277	Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. <i>Journal of Urology</i> , 2021 , 206, 298-307	2.5	5
276	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	3
275	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2926-2937	2.2	10
274	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021 , 155, 165-171	1.6	4
273	Predictive biomarkers of overall survival in patients with renal cell carcinoma treated with interferon alpha +/- bevacizumab: Results from CALGB 90206 (Alliance).. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
272	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020 , 38, 761-766	24.3	12
271	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	18

270	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa003	4.6	1
269	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3032-3041	2.2	13
268	Palbociclib in Patients With Non-Small-Cell Lung Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.. <i>JCO Precision Oncology</i> , 2020 , 4, 757-766	3.6	15
267	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
266	Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2020 , 31, 930-941	10.3	8
265	Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4637-4637	2.2	6
264	Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5561-5561	2.2	3
263	Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 122-122	2.2	7
262	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 132-132	2.2	18
261	Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 133-133	2.2	12
260	AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 184-184	2.2	1
259	Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 96-96	2.2	3
258	Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 183-183	2.2	1
257	Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 84-84	2.2	
256	Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 147-147 ²⁻²		
255	Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5567-5567	2.2	2
254	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020 , 59, 225-239	5	14
253	Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. <i>Oncologist</i> , 2020 , 25, e405-e411	5.7	1

252	Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 222-229.e2	3.3	1
251	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Targeted Oncology</i> , 2020 , 15, 743-750	5	9
250	Best (but oft-forgotten) practices: sample size and power calculation for a dietary intervention trial with episodically consumed foods. <i>American Journal of Clinical Nutrition</i> , 2020 , 112, 920-925	7	0
249	Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3042-3050	2.2	17
248	Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Targeted Oncology</i> , 2020 , 15, 733-741	5	10
247	Score and deviance residuals based on the full likelihood approach in survival analysis. <i>Pharmaceutical Statistics</i> , 2020 , 19, 940-954	1	0
246	Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes. <i>Lifetime Data Analysis</i> , 2020 , 26, 266-291	1.3	3
245	Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 66-73	6.2	4
244	Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 79.e15-79.e22	2.8	12
243	Comparison of regression imputation methods of baseline covariates that predict survival outcomes. <i>Journal of Clinical and Translational Science</i> , 2020 , 5, e40	0.4	1
242	Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2019 , 79, 1752-1761	4.2	1
241	Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019 , 5, 975-983	13.4	142
240	On the use of min-max combination of biomarkers to maximize the partial area under the ROC curve. <i>Journal of Probability and Statistics</i> , 2019 , 2019,	0.6	2
239	Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2019 , 14, e0216934	3.7	9
238	A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz002	4.6	18
237	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1120-1129	2.2	171
236	Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 137-143	5.1	1
235	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019 , 24, 1497-1501	5.7	11

234	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2184-2186	2.2	4
233	Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1014-1014	2.2	23
232	CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4503-4503	2.2	32
231	Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5008-5008	2.2	21
230	CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5079-5079	2.2	7
229	Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9041-9041	2.2	6
228	Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 186-186	2.2	2
227	Developing and Validating Prognostic Models of Clinical Outcomes 2019 , 347-374		1
226	External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5022-5022	2.2	
225	Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16579-e16579	2.2	
224	PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5021-5021	2.2	
223	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. <i>Journal of Clinical Oncology</i> , 2019 , 37, 403-410	2.2	56
222	Advancing Precision Oncology Through Biomarker-Driven Trials: Theory vs. Practice. <i>Chance</i> , 2019 , 32, 23-31	1	1
221	Improved Reporting in Abstracts When Uncertainty Is Inevitable. <i>JAMA Network Open</i> , 2019 , 2, e1917543	0.4	
220	Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern Oncology. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	6
219	Palbociclib in Patients With Pancreatic and Biliary Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-8	3.6	14
218	Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 309-316	6.2	8
217	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018 , 94, 115-125	7.5	179

216	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2	313
215	Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. <i>Annals of Oncology</i> , 2018 , 29, 23-25	10.3	5
214	Identification of a Genomic Region between and Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018 , 24, 4734-4744	12.9	8
213	Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2532-2532	2.2	3
212	The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5004-5004	2.2	3
211	Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, LBA5005-LBA5005	2.2	2
210	Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, LBA5009-LBA5009	2.2	13
209	Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11-11	2.2	2
208	Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 582-582	2.2	5
207	Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 160-160	2.2	1
206	Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5029-5029	2.2	
205	Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	53
204	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 812-818	2.2	69
203	Combined Performance of Screening and Variable Selection Methods in Ultra-High Dimensional Data in Predicting Time-To-Event Outcomes. <i>Diagnostic and Prognostic Research</i> , 2018 , 2,	5.5	7
202	A Simple Method for Deriving the Confidence Regions for the Penalized Cox Model via the Minimax Perturbation. <i>Communications in Statistics - Theory and Methods</i> , 2017 , 46, 4791-4808	0.5	4
201	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2017 , 81, 228-236	7.5	61
200	Reply to B. Rini et al and S. Buti et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1859-1860	2.2	1
199	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3097-3104	2.2	215

198	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2017 , 23, 6802-6811	12.9	50
197	Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. <i>Journal of Surgical Oncology</i> , 2017 , 116, 969-982	2.8	48
196	Comparison of fertility monitoring guidelines using completed phase III oncology trials. <i>Clinical Trials</i> , 2017 , 14, 48-58	2.2	9
195	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 591-597	2.2	434
194	Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. <i>Prostate</i> , 2017 , 77, 385-395	4.2	4
193	Risk Models for Individualized Prognosis in the Practice of Precision Oncology 2017 , 47-52		0
192	Penis 2017 , 709-722		1
191	Prostate 2017 , 723-734		3
190	Testis 2017 , 735-743		4
189	Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5034-5034	2.2	
188	Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5067-5067	2.2	
187	Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4522-4522	2.2	1
186	Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP). <i>Annals of Oncology</i> , 2016 , 27, vi243	10.3	8
185	Residential metal contamination and potential health risks of exposure in adobe brick houses in Potosí, Bolivia. <i>Science of the Total Environment</i> , 2016 , 562, 237-246	10.2	9
184	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 378-388	21.7	240
183	A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2016 , 19, 100-6	6.2	11
182	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1402-18	2.2	666
181	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1652-9	2.2	217

180	Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016 , 19, 40-5	6.2	6
179	Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5023-5023	2.2	4
178	Phase Ib trial of cabazitaxel and tasquinimod in men with heavily pretreated metastatic castration resistant prostate cancer (mCRPC): The CATCH trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 190-190	2.2	1
177	Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 275-275	2.2	
176	Impact of therapy on gene expression in high-risk prostate cancer (PCA) treated with neoadjuvant docetaxel and androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8-8	2.2	
175	Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS5093-TPS5093	2.2	
174	High Dimensional Variable Selection with Error Control. <i>BioMed Research International</i> , 2016 , 2016, 8209-8213	4.53	6
173	CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. <i>Annals of Oncology</i> , 2016 , 27, vi566	10.3	8
172	Critical Assessment of Clinical Prognostic Tools in Melanoma. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2753-2761	3.61	36
171	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. <i>Clinical Cancer Research</i> , 2016 , 22, 4890-4900	12.9	36
170	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 370-4	220.7	219
169	Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 110.e1-9	2.8	17
168	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015 , 26, 1589-604	10.3	220
167	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). <i>Cancer</i> , 2015 , 121, 1025-31	6.4	25
166	Independent data monitoring committees: an update and overview. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 143-8	2.8	10
165	Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?. <i>Cancer</i> , 2015 , 121, 1906	6.4	
164	Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome. <i>Communications in Statistics - Theory and Methods</i> , 2015 , 44, 275-285	0.5	2
163	MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE). <i>Journal of Urology</i> , 2015 , 193,	2.5	1

162	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). <i>EBioMedicine</i> , 2015 , 2, 1814-20	8.8	11
161	A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events. <i>Pharmaceutical Statistics</i> , 2015 , 14, 273-83	1	
160	Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1576-89	8.9	28
159	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv261	9.7	35
158	Mercury hair levels and factors that influence exposure for residents of Huancavelica, Peru. <i>Environmental Geochemistry and Health</i> , 2015 , 37, 507-14	4.7	10
157	Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4507-4507	2.2	8
156	The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5000-5000	2.2	19
155	Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5025-5025	2.2	6
154	A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy (RT) in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 35-35	2.2	
153	Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). <i>Journal of Clinical Oncology</i> , 2014 , 32, 1143-50	2.2	166
152	Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 671-7	2.2	322
151	Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2014 , 120, 52-60	6.4	32
150	Adjusting for misclassification in a stratified biomarker clinical trial. <i>Statistics in Medicine</i> , 2014 , 33, 3100-13	2.3	13
149	Reply to F. Valcamonico et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3685	2.2	
148	The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5002-5002	2.2	6
147	Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4532-4532	2.2	1
146	Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16061-e16061	2.2	
145	A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9612-9612	2.2	

144	Reply to M A Khattak et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 972-3	2.2	
143	On model specification and selection of the Cox proportional hazards model. <i>Statistics in Medicine</i> , 2013 , 32, 4609-23	2.3	7
142	A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 397-406	3.3	47
141	Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1729-37	9.7	113
140	Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 499-503	9.7	63
139	Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3944-50	2.2	71
138	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). <i>Cancer</i> , 2013 , 119, 3636-43	6.4	16
137	A survey of clinical prediction tools in colorectal and lung cancers and melanoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1592-1592	2.2	4
136	Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5031-5031	2.2	3
135	A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 105-105	2.2	1
134	Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 27-27	2.2	2
133	Residential mercury contamination in adobe brick homes in Huancavelica, Peru. <i>PLoS ONE</i> , 2013 , 8, e75139	1.7	12
132	A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 24-24	2.2	
131	ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS4590-TPS4590	2.2	1
130	Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. <i>European Urology</i> , 2012 , 61, 549-59	10.2	133
129	Estimations of historical atmospheric mercury concentrations from mercury refining and present-day soil concentrations of total mercury in Huancavelica, Peru. <i>Science of the Total Environment</i> , 2012 , 426, 146-54	10.2	13
128	Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. <i>Pain Medicine</i> , 2012 , 13, 1417-24	2.8	13
127	Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease. <i>Statistics in Medicine</i> , 2012 , 31, 29-44	2.3	

126	Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1534-40	2.2	379
125	Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. <i>Cancer</i> , 2012 , 118, 4139-47	6.4	15
124	Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3402-7	2.2	122
123	Design issues in randomized phase II/III trials. <i>Journal of Clinical Oncology</i> , 2012 , 30, 667-71	2.2	48
122	Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4655-4655	2.2	2
121	Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 129-129	2.2	2
120	Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 200-200	2.2	4
119	The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4667-4667	2.2	
118	External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4592-4592	2.2	2
117	Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4515-4515	2.2	0
116	Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints. <i>Journal of Biometrics & Biostatistics</i> , 2012 , 7, 15	4	3
115	Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. <i>European Journal of Cancer</i> , 2011 , 47, 683-9	7.5	80
114	Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí/Bolivia. <i>Atmospheric Environment</i> , 2011 , 45, 7619-7626	5.3	29
113	A min-max combination of biomarkers to improve diagnostic accuracy. <i>Statistics in Medicine</i> , 2011 , 30, 2005-14	2.3	41
112	A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. <i>Cancer</i> , 2011 , 117, 526-33	6.4	62
111	Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. <i>Cancer</i> , 2011 , 117, 5579-88	6.4	21
110	Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 189-189	2.2	6
109	Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. <i>Annals of Oncology</i> , 2010 , 21, 312-318	10.3	32

108	Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2137-43	2.2	661
107	Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 942-9	9.7	39
106	A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 3057-66	12.9	61
105	Bevacizumab and everolimus in renal cancer: a rational way forward. <i>Journal of Clinical Oncology</i> , 2010 , 28, e692-3; author reply e694	2.2	4
104	The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. <i>European Journal of Cancer</i> , 2010 , 46, 517-25	7.5	107
103	The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. <i>Urology</i> , 2010 , 75, 623-9	1.6	8
102	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 663-74	7.4	249
101	The importance of identifying and validating prognostic factors in oncology. <i>Seminars in Oncology</i> , 2010 , 37, e9-18	5.5	31
100	Impact of tamsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study.. <i>Journal of Clinical Oncology</i> , 2010 , 28, TPS249-TPS249	2.2	2
99	A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.. <i>Journal of Clinical Oncology</i> , 2010 , 28, LBA4511-LBA4511	2.2	62
98	Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 256-66	9.7	381
97	Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2766-71	2.2	81
96	The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2009 , 12, 88-93	6.2	22
95	A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. <i>Annals of Oncology</i> , 2009 , 20, 1074-9 ^{10.3}	10.3	85
94	Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). <i>Clinical Genitourinary Cancer</i> , 2009 , 7, E66-70	3.3	5
93	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. <i>European Urology Supplements</i> , 2009 , 8, 738-746	0.9	4
92	A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. <i>Clinical Genitourinary Cancer</i> , 2008 , 6, 110-6	3.3	9
91	p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). <i>Urology</i> , 2008 , 71, 933-7	1.6	17

90	Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 300-7	2.8	2
89	Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1148-59	2.2	1651
88	Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. <i>American Journal of Epidemiology</i> , 2008 , 167, 1059-69	3.8	89
87	Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 585-93	4	26
86	Flexible Frames and Control Sampling in Case-Control Studies: Weighters (Survey Statisticians) Versus Anti-Weighters (Epidemiologists). <i>American Statistician</i> , 2008 , 62, 307-313	5	4
85	Circulating levels of inflammatory cytokines and risk of colorectal adenomas. <i>Cancer Research</i> , 2008 , 68, 323-8	10.1	204
84	Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5422-8	2.2	780
83	Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. <i>American Journal of Epidemiology</i> , 2008 , 168, 1292-300	3.8	10
82	Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. <i>Annals of Oncology</i> , 2008 , 19, 946-50	10.3	41
81	Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2544-9	2.2	147
80	Sample size selection in clinical trials when population means are subject to a partial order: one-sided ordered alternatives. <i>Journal of Applied Statistics</i> , 2008 , 35, 583-600	1	2
79	A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. <i>BJU International</i> , 2008 , 101, 20-5	5.6	34
78	Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. <i>Cancer</i> , 2008 , 113, 3137-45	6.4	11
77	Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 2-15	4	13
76	Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, 814-9	4	14
75	Second-line chemotherapy for advanced hormone-refractory prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 118-22, 127-32	0.6	22
74	American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2464-72	2.2	350
73	The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. <i>Journal of Urology</i> , 2007 , 177, 531-4	2.5	17

72	Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. <i>Cancer</i> , 2007 , 110, 1478-84	6.4	46
71	ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary. <i>Journal of Oncology Practice</i> , 2007 , 3, 236	3.1	2
70	Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 473-80	4	46
69	Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. <i>Clinical Cancer Research</i> , 2007 , 13, 2030-7	12.9	78
68	A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. <i>Cancer</i> , 2006 , 107, 1273-9	6.4	60
67	Analgesic drug use and risk of ovarian cancer. <i>Epidemiology</i> , 2006 , 17, 104-7	3.1	60
66	Activities and accomplishments of the cancer and leukemia group B genitourinary committee. <i>Clinical Cancer Research</i> , 2006 , 12, 3596s-600s	12.9	2
65	Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. <i>Journal of Urology</i> , 2006 , 176, 81-6	2.5	20
64	Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. <i>Clinical Genitourinary Cancer</i> , 2006 , 4, 269-74	3.3	33
63	Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 778-85	4.7	33
62	Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. <i>Urology</i> , 2005 , 66, 386-91	1.6	80
61	Antidepressant medication use [corrected] and risk of ovarian cancer. <i>Obstetrics and Gynecology</i> , 2005 , 105, 725-30	4.9	16
60	Flushing and papules in a middle-aged woman. <i>Obstetrics and Gynecology</i> , 2005 , 105, 397-401	4.9	3
59	Menopausal hormones and risk of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2005 , 193, 76-82	6.4	25
58	Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. <i>Gynecologic Oncology</i> , 2005 , 97, 543-9	4.9	16
57	Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women. <i>Cancer Causes and Control</i> , 2005 , 16, 955-63	2.8	37
56	The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. <i>Clinical Cancer Research</i> , 2005 , 11, 1815-20	12.9	136
55	Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. <i>Clinical Cancer Research</i> , 2005 , 11, 8109-13	12.9	22

54	Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2434-5; author reply 2435	2.2	21
53	Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). <i>Journal of Clinical Oncology</i> , 2004 , 22, 1025-33	2.2	410
52	Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 2004 , 22, 537-56	2.2	167
51	Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 2584-6	12.9	137
50	Sample size determination for comparing several survival curves with unequal allocations. <i>Statistics in Medicine</i> , 2004 , 23, 1793-815	2.3	21
49	Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. <i>Cancer</i> , 2004 , 101, 370-8	6.4	89
48	Impact of race on survival in men with metastatic hormone-refractory prostate cancer. <i>Urology</i> , 2004 , 64, 212-7	1.6	25
47	9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004 , 22, 398-403	2.8	7
46	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. <i>Blood</i> , 2004 , 104, 810-810	2.2	2
45	Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. <i>Journal of Clinical Oncology</i> , 2003 , 21, 490-5	2.2	48
44	Analysis of survival data with missing measurements of a time-dependent binary covariate. <i>Journal of Biopharmaceutical Statistics</i> , 2003 , 13, 253-70	1.3	2
43	Overview of bladder cancer trials in the Cancer and Leukemia Group B. <i>Cancer</i> , 2003 , 97, 2090-8	6.4	31
42	A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. <i>Cancer</i> , 2003 , 98, 2592-8	6.4	81
41	A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. <i>New England Journal of Medicine</i> , 2003 , 348, 883-90	59.2	946
40	Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1232-7	2.2	566
39	Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2673-8	2.2	306
38	No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003 , 12, 226-7	4	9
37	Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. <i>Cancer</i> , 2002 , 94, 665-72	6.4	14

36	Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). <i>Cancer Causes and Control</i> , 2002 , 13, 807-11	2.8	42
35	Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3369-75	2.2	46
34	Effects of a mammography decision-making intervention at 12 and 24 months. <i>American Journal of Preventive Medicine</i> , 2002 , 22, 247-57	6.1	122
33	A tailored intervention to aid decision-making about hormone replacement therapy. <i>American Journal of Public Health</i> , 2002 , 92, 1112-4	5.1	37
32	The short-term impact of tailored mammography decision-making interventions. <i>Patient Education and Counseling</i> , 2001 , 43, 269-85	3.1	70
31	Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial. <i>Cancer</i> , 2001 , 91, 1040-1045	6.4	36
30	Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second-Line Hormonal Therapy (CALGB 9181). <i>Prostate Journal</i> , 2001 , 3, 18-25		5
29	Age at natural menopause and the risk of epithelial ovarian cancer. <i>Obstetrics and Gynecology</i> , 2001 , 98, 85-90	4.9	30
28	Women's interest in chemoprevention for breast cancer. <i>Archives of Internal Medicine</i> , 2001 , 161, 1639-44		40
27	Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3025-8	2.2	51
26	Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. <i>Cancer and Leukemia Group B. Journal of Clinical Oncology</i> , 2001 , 19, 2509-16	2.2	276
25	A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. <i>Cancer</i> , 2000 , 88, 825-834	6.4	65
24	The impact of abnormal mammograms on psychosocial outcomes and subsequent screening. <i>Psycho-Oncology</i> , 2000 , 9, 402-10	3.9	57
23	Can tailored interventions increase mammography use among HMO women?. <i>American Journal of Preventive Medicine</i> , 2000 , 18, 1-10	6.1	84
22	Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. <i>Obstetrics and Gynecology</i> , 2000 , 95, 119-27	4.9	27
21	Maximizing the motivational impact of feedback of lung cancer susceptibility on smokers' desire to quit. <i>Journal of Health Communication</i> , 2000 , 5, 229-41	2.5	35
20	A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma 2000 , 88, 825		3
19	The impact of abnormal mammograms on psychosocial outcomes and subsequent screening 2000 , 9, 402		6

18	Factors associated with repeat mammography screening. <i>Journal of Family Practice</i> , 2000 , 49, 1104-12	0.2	55
17	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3461-7	2.2	839
16	Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2506-13	2.2	731
15	Confusion about mammography: prevalence and consequences. <i>Journal of Womens Health and Gender-Based Medicine</i> , 1999 , 8, 509-20		20
14	Attitudes and Knowledge Associated with being Undecided about Hormone Replacement Therapy: Results from a Community Sample. <i>Womens Health Issues</i> , 1999 , 9, 330-337	2.6	3
13	p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. <i>Archives of Pathology and Laboratory Medicine</i> , 1999 , 123, 310-6	5	18
12	Validation of a breast cancer risk assessment model in women with a positive family history. <i>Journal of the National Cancer Institute</i> , 1994 , 86, 620-5	9.7	145
11	The Texas Breast Screening Project: Part II. Demographics, risk profiles, and health practices of participants. <i>Southern Medical Journal</i> , 1993 , 86, 391-6	0.6	11
10	The Texas Breast Screening Project: Part I. Mammographic and clinical results. <i>Southern Medical Journal</i> , 1993 , 86, 385-90	0.6	4
9	Incidence of Autoimmune Disease in Patients after Breast Reconstruction with Silicone Gel Implants Versus Autogenous Tissue. <i>Annals of Plastic Surgery</i> , 1993 , 31, 1-6	1.7	61
8	Factors associated with perceived risk of breast cancer among women attending a screening program. <i>Breast Cancer Research and Treatment</i> , 1993 , 28, 137-44	4.4	83
7	Reliability and validity of self and proxy reporting of morbidity data: a case study from Beirut, Lebanon. <i>International Journal of Epidemiology</i> , 1992 , 21, 607-12	7.8	32
6	Low incidence of familial breast cancer among Hispanic women. <i>Cancer Causes and Control</i> , 1992 , 3, 377-82		21
5	Breast cancer screening behaviors and attitudes in three racial/ethnic groups. <i>Cancer</i> , 1992 , 69, 165-74	6.4	122
4	Epidemiology of primary health problems in Beirut. <i>Journal of Epidemiology and Community Health</i> , 1989 , 43, 315-8	5.1	11
3	Hospital visitors as controls. <i>American Journal of Epidemiology</i> , 1988 , 127, 404-6	3.8	9
2	Measures of social class based on education for use in health studies in developing countries. <i>Journal of Epidemiology and Community Health</i> , 1987 , 41, 173-9	5.1	21
1	Perception of consanguineous marriages and their genetic effects among a sample of couples from Beirut. <i>American Journal of Medical Genetics Part A</i> , 1986 , 25, 299-306		43

